Newly revised optimal care pathways (OCPs) provide best practice information for the treatment and care of people living with acute myeloid leukaemia (AML), and diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL).
In this honest, humourous, and heartfelt first-person narrative, Diane Autio shares her experiences of being diagnosed with acute myeloid leukaemia (AML).
Dr Chun Fong believes that testing for minimal residual disease (MRD) is part of the answer.
A new platform trial, a world first, could have transformative implications for people with resistant AML.
Diagnosed with two blood cancers, Nick's world changed instantly. Then transplant complications challenged him in ways he didn't expect.
Edward Rhoades and his mum, Jan, knew they wanted to give others impacted by blood cancer a brighter future after he suffered from the debilitating side-effects of a stem cell transplant, to which he eventually lost his life.
Delighted, really relieved, and excited was Deborah Henderson’s response to her nine-month review following CAR T-cell therapy last year.
Yael Morris was very young – only 34 years old, 28 weeks pregnant, and living in Darwin – when she was diagnosed with CLL 20 years ago.
Dr Piers Blombery explains the basics of molecular testing which informs the treatment of blood cancer.
Dr Piers Blombery specialises in genomic testing and heads Australia’s largest haematology laboratory.
